Table 1 Case reports of cancer associated retinopathy with breast cancer
Author | Age | Symptom | Diagnosis of BC | Stage of BC | Chemotherapy | Treatment of CAR | Antibody | From CAR onset to treatment | Course | Pathology |
|---|---|---|---|---|---|---|---|---|---|---|
Holz FG(1997) [3] | 53 | Blurred vision/reduce of dark adaptation paracentral scotoma | 5 years 1 month before | T2N0M0 | Done (epirubicin/treosulfan) | Steroid therapy methotrexate | Recoverin: - | No record | No remission | No record |
62 | Photopsia photosensitivity blurred vision | 6 years before | T1bN0M0 | Steroid therapy methotrexate | No performed | 4 months | No remission | No record | ||
Ejma M(2008) [4] | 54 | Decreased vision in the dark photopsia photosensitivity | 8 months before | T4dN0M+ | Done (FAC) | None | Recoverin: - α-enolase: + GCAPs: - retinal arrestin: - | – | No remission (died) | No record |
Anastasakis(2011) [5] | 62 | Shimmering Photopsia myodesopsia | 2 months after | TxNxM+(PUL,PAN) | Done (no record) | Chemotherapy | No performed | 2 months | Normalized | Lobular ca. |
present case | 50 | Decreased vision photopsia photosensitivity defect of visual field | 30 days before | T2N1M0 | Done (CDDP+VP16,EC,DTX) | Steroid therapy | Recoverin: - | 59 days | Improved | Invasive ca. with neuroendocrine features |